More SCENESSE® treatment access changing lives
Ongoing supply of SCENESSE® to EPP patients
Growth in treatment centres, patients, prescriptions filled
Special access program launched in Canada
Application submitted for label expansion to treat adolescent EPP patients (aged 12–17 years)
Start of adolescent patients treated
Melanocortin portfolio
PRÉNUMBRA® Instant
Developed, first use in second stroke study
NEURACTHEL® Instant
Instant formulation of ACTH progressed to cGMP manufacture of validation batches and preparation of Drug Master File
Afamelanotide in the clinic
DNA Repair
- Control study of healthy volunteers completed
- Two studies in xeroderma pigmentosum (XP) underway
- Initial results of one XP study presented at the 2023 American Academy of Dermatology Meeting (reduction in key markers of photodamage)
Arterial Ischaemic Stroke
- PRÉNUMBRA® study underway
Repigmentation
- Vitiligo monotherapy study underway
- Large combination therapy study in planning
Variegate Porphyria
- Study underway
PhotoCosmetics
First polychromatic product CYACÊLLE, pilot launched 1 March (EU)
Focus on highest risk audiences
Three product ranges in development – radiant polychromatic protection, DNA-Repair and melanogenesis
Financial performance
24% growth in revenues
Seventh consecutive annual profit
Sixth consecutive annual dividend declared
Controlled increase in expenses
Continued increase in cash reserves
Active communication of CLINUVEL’s story
57 company announcements
6 Soirées and Investor Briefings
6 Investor Conferences
2 Strategic Updates – V and VI
CUVA and CUVIP campaigns launched
Targeted social media posts